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Analytical Methods: 
 
Samples were processed serially, rather than in parallel, to avoid cross-
contamination.  About 30 g of rock was washed then sonicated in distilled water for ~10 
s.  Samples were air-dried at room temperature and crushed into <5 cm pieces with a jaw-
type rock crusher that had been cleaned 4x each with acetone then dichloromethane 
(DCM).  These large pieces were then sonicated with ~250 ml 9:1 DCM:MeOH for 2 
minutes.  Solvent was collected and rock pieces were crushed to <1 cm on a smaller rock 
crusher cleaned as before.  Ultrasonic extraction was repeated, and the sample was 
powdered in a shatterbox that was cleaned by grinding quartz sand followed by 4x 
acetone and DCM cleaning. 
 The powdered rock was extracted in a microwave-accelerated reaction system 
(MARSXpress): 20 g of rock was split equally between 5 clean Teflon vessels, 25 ml of 
9:1 DCM/MeOH was added to each vessel, and the samples were extracted at 100°C for 
15 minutes with stirring.  Extracts were filtered through combusted glass-fiber filters to 
remove particulates, and solvent was evaporated to ~30ml under nitrogen at 35°C, taking 
care not to allow samples to completely dry.  Elemental sulfur was removed by filtration 
through activated copper (~3.5g, -40+100 mesh), and the S°-free extract was evaporated 
to near-dryness under N2.  Extract was transferred to a vial with hexane, solvent volume 
was reduced under N2 to 100µl, and then analyzed by gas chromatography/mass 
spectrometry (GC/MS).  Extracts from the two preliminary extractions were prepared and 
analyzed following the same procedures.  All samples were analyzed on a 
ThermoFinnigan Trace GC-DSQ quadrupole MS equipped with a DB-5MS capillary 
column (30 m x 0.25 mm x 0.25 µm film thickness).  1 µl aliquots were injected into a 
PTV injector (35°C hold for 3 min, 14.5°C/s to 200°C then 12°C/s to 350°C with a 3 
minute hold). The column oven was programmed at 20°C/min to 130°C, then 5°C/min to 
320°C with a 20 minute hold.   
After initial GC/MS analyses, each of the final extracts was separated into 
fractions by column chromatography.  Polar compounds (mainly phthalates and other 
plasticizers) were first separated from hydrocarbons on 1.0g silica gel (100-200 mesh, 5% 
deactivated) dry-packed into Pasteur pipettes.  Hydrocarbons were eluted with 3.75 ml 
8:2 Hexane:DCM (F1) and polar compounds were eluted with 6ml 7:3 DCM:MeOH 
(F2). Saturates and aromatics were then separated on silica gel with 10% AgNO3 dry-
packed into Pasteur pipettes. Aliphatic compounds were eluted with 5ml hexane (F1a) 
and aromatic compounds were eluted with 4ml DCM (F1b). The three fractions (polar, 
aromatic, aliphatic) were concentrated under N2, and analyzed by GCMS using the same 
conditions as above. 
Laboratory blanks of the solvents, copper, silica gel, silver-impregnated silica gel 
and MARS vessels were analyzed, and a block of pre-baked basalt was spiked with a 
standard lipid solution and then subjected to the entire analytical procedure. No 
hydrocarbons, oil residues or UCM were observed in any of the blanks.  Biomarker yields 
were confirmed with replicate extractions of several samples. Biomarker identities were 
confirmed by metastable-reaction monitoring GCMS analyses of split aliquots from our 
extracts by E. Grosjean and R. Summons (Massachusetts Institute of Technology). TOC 
abundances were measured by a Eurovector elemental analyzer in line with an Isoprime 
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gas source isotope ratio mass spectrometer (University of Maryland) and also by Dumas 
combustion. 
 
 
Figure S1: Selected-ion GC/MS chromatograms for the eight samples showing 
distributions of hopanes (left; m/z 191), steranes (middle; m/z 217) and alkylated 2,3,6-
trimethylbenzenes (right; m/z 133).  For each column, chromatograms are depicted at the 
same scale; the mass spectrum of the compound marked with a dot is shown in Figure S2. 
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Figure S2:  The mass spectrum of the alkylated 2,3,6-trimethylbenzene indicated in 
Figure S1.  For comparison, the NIST mass spectrum for 1-(3-methylbutyl)-2,3,6-
trimethylbenzene, a shorter-chain alkylated 2,3,6-trimethylbenzene, is shown in inset 
(NIST #245506). 
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Table S1: Kerogen and bitumen contents of samples analyzed for biomarker content.   
sample 
depth 
(m) 
Lithology 
CaCO3 
(%) 
Corg
(%) 
H/C of 
kerogen
Extract 
yield 
(µg/g) 
δ13C 
kerogen 
(‰) 
δ13C 
bulk 
extract 
(‰) 
759 
rhythmic 
marls 
8 0.11  0.23 5.0  -25.7 -24.1 
783 
rhythmic 
marls 
43 0.08  0.10 7.7 -29.1 -23.7  
805 
black 
shale 
6 0.43 0.11  8.1 -25.1 -25.3 
810 
black 
shale 
6 0.44 0.54 4.8  -26.0 -25.6 
812 
black 
shale 
8 0.69 0.06  10.8 -24.9 -24.7 
816 
black 
carbonate 
91 0.86 0.97  5.8 -22.6 -23.4 
817 
black 
shale 
3 1.01 0.04  13.5 -26.3 -24.2 
858 diamictite 95 0.01  0.09 2.4 -21.5 -24.5 
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Table S2: Biomarker ratios in samples from organic-rich black shale samples in core 
MAF 42-88. Ratios were measured using standard methods (S1).  The first six ratios 
reflect the thermal maturity of the organic matter, comparing the relative abundances of 
the biomarkers’ biologic form (e.g, 20R steranes) to the isomers created by thermal 
alteration (e.g., 20S steranes).  The last seven ratios reflect changes in biologic input, 
comparing the relative abundances of biomarkers from different organisms (e.g., steranes 
to hopanes).  The two numbers for sample 805 m represent replicate determinations of 
the biomarker ratios.   
 
 Depth 805 810 812 816 817 
C27 Ts/( C27 Ts+ C27Tm) 0.37/0.37 0.42 0.58 0.40 0.39 
C29TS/ C29 hopane 0.17/0.18 0.16 0.24 0.19 0.20 
(Ts+Tm)/C29 hopane 0.61/0.61 0.62 0.98 0.58 0.64 
Diasterane/sterane 0.42/0.42 0.52 0.88 0.47 0.45 
C29 sterane 20S /(20S+20R) 0.49/0.49 0.53 0.55 0.50 0.51 M
AT
U
RI
TY
 
PA
RA
M
ET
E
RS
 
C29 sterane αββ/(ααα+αββ) 0.47/0.47 0.51 0.54 0.46 0.50 
       
C27 sterane /(C27 +C28+C29 steranes) 0.50/0.50 0.50 0.46 0.45 0.35 
C28 sterane /(C27 +C28+C29 steranes) 0.21/0.21 0.20 0.21 0.25 0.27 
C29 sterane /(C27 +C28+C29 steranes) 0.29/0.29 0.30 0.33 0.30 0.39 
C29 hopane/C30 hopane 1.03/1.02 1.04 1.02 1.05 1.09 
C30 hopane/C31 hopane 1.73/1.74 1.65 1.69 1.71 1.81 
2α-Me ratio (%) 9.0/9.0 8.5 9.6 10.8 8.5 
SO
U
RC
E 
PA
RA
M
ET
ER
S 
Sterane/hopanes 0.54/0.54 0.67 1.25 0.68 0.63 
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Table S3: Concentrations (pg/g) of selected biomarkers found in core MAF 42-88.  
Biomarker concentrations were determined using peak areas from metastable-reaction 
monitoring GCMS chromatograms versus a coinjected standard (50ng D4 24-
ethylcholestane).   
 
Depth 805 810 812 816 817 
2α-Me hopanes 1.98 1.36 1.30 1.35 2.96 
Cholestane (C27) 18.27 16.93 27.06 11.77 24.89 
Ergostane (C28) 7.74 6.69 12.46 6.40 19.09 
Stigmastane (C29) 10.78 10.30 19.64 7.80 27.98 
C29 Hopane  20.77 15.17 12.49 11.63 34.82 
C30 Hopane  20.13 14.58 12.28 11.13 31.96 
C31 Hopane  11.60 8.81 7.28 6.52 17.65 
Gammacerane 2.00 0.38 0.56 1.05 2.63 
3β-Me hopanes 0.73 0.15 0.62 0.52 0.95 
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